Q2 2022 Ascelia Pharma AB Earnings Call Transcript
Thank you, and welcome, everyone, to the webcast for Ascelia Pharma's Q2 report in 2022. So together with the rest of the management team, we're pleased and looking forward to updating you on the results and the progress in the quarter. Now, please turn to page number 2.
In this presentation, we will be making certain forward-looking statements, so please pay attention to this page before turning to page number 3.
Ascelia Pharma is dedicating to improve the life of people living with cancer by offering better treatment options. In particular, we focus on rare cancer conditions. Our business model is to identify, develop, and commercialize novel drugs that address unmet medical needs within orphan oncology.
We have two drugs in clinical development. Orviglance is in an ongoing Phase 3 clinical study. Once it gets to market, it will be the only product targeting an addressable market of opportunity of $500 million to $600 million annually. Oncoral is ready to start Phase 2 in the treatment of gastric cancer based on encouraging results
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |